Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
ProMIS Neurosciences Inc
PMN
Healthcare
Biotechnology
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine...
applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:PMN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(97)
•••
G1945V
X
View Profile
View Bullboard History
Comment by
G1945V
on Apr 04, 2024 10:11am
RE:New Press Release - ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
"Bloom Burton & Co. Healthcare Investor Conference (Toronto, Canada)" Ya, more false hope for Canadian Biotech startups! jmo G1945V
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 04, 2024 7:00am
New Press Release - ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 04, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that...
read article.
Silvercorp to Acquire Adventus, Creating a Diversified Mining Company
posted May 02, 2024 9:00am by
Adventus Mining Corp.
-
|
Under the terms of the Arrangement Agreement, each holder of the common shares of Adventus will receive 0.1015 of one Silvercorp common share in exchange for each Adventus Share at the effective time of the Transaction. The Exchange Ratio implies consideration of C$0.50 per Adventus Share ...read more
(82)
•••
Gbathat
X
View Profile
View Bullboard History
Comment by
Gbathat
on Apr 02, 2024 8:33pm
RE:RE:annual numbers
lol, yes it does. and I don't mind being called out. I'll be right someday, maybe, lol.
(38)
•••
BottomBroker
X
View Profile
View Bullboard History
Comment by
BottomBroker
on Apr 02, 2024 12:58pm
RE:annual numbers
Man, if I had a nickle for every time I've heard that "this year will be an exciting year"... And I'm not calling you out, Gbathat. I've said it myself. Oh well, hope
...more
(0)
•••
Terrylaz
X
View Profile
View Bullboard History
Comment by
Terrylaz
on Apr 01, 2024 8:56pm
RE:annual numbers
Acumen has posted what looks like a phase 2/3 potential combination. 126 locations, 2040 people, US,Canada,France, Germany, Italy, UK, Spain, Poland. Estimated completion year 2031.
(82)
•••
Gbathat
X
View Profile
View Bullboard History
Post by
Gbathat
on Apr 01, 2024 4:47pm
annual numbers
I was glad to see burn rate was significantly lower than 2022. Hopefully the $12M cash on hand can last a while. I'd expect them to raise money for Phase 2 after the mid-year data becomes
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 01, 2024 4:15pm
New Press Release - ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024 CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company...
read article.
(30)
•••
bball67
X
View Profile
View Bullboard History
Post by
bball67
on Apr 01, 2024 11:19am
10k filing today
Normally Promis has filed their Q4 earnings and annual 10k report in the first 10 days of March. I have been wondering why they have waited so long. The 90 day mandatory filing was extended to April 1
...more
(82)
•••
Gbathat
X
View Profile
View Bullboard History
Comment by
Gbathat
on Mar 26, 2024 7:20pm
RE:RE:RE:Acumenpharma
Yes, very odd. They seemed optimistic on their earnings call. https://seekingalpha.com/article/4680495-acumen-pharmaceuticals-inc-abos-q4-2023-earnings-call-transcript
(107)
•••
M101
X
View Profile
View Bullboard History
Comment by
M101
on Mar 26, 2024 6:33pm
RE:RE:RE:RE:Acumenpharma
oops, guess I totally missed the thread, my bad.
(107)
•••
M101
X
View Profile
View Bullboard History
Comment by
M101
on Mar 26, 2024 6:31pm
RE:RE:RE:Acumenpharma
You mean your pp bet is flatlining? Because nothing has changed, you knew then that they would be raising again at least for P2 if not P1b, and now the market is thinking it could be at the same price
...more
(30)
•••
bball67
X
View Profile
View Bullboard History
Comment by
bball67
on Mar 26, 2024 2:34pm
RE:RE:Acumenpharma
Something not right. $300M cash and $215m market cap. Under water. Another one bites the dust?
(44)
•••
FarmerBetsy
X
View Profile
View Bullboard History
Comment by
FarmerBetsy
on Mar 26, 2024 12:08pm
RE:Acumenpharma
Acumenpharma reported year end results this morning. Interesting they have not started phase 2 after wrapping up phay1 last July.
(107)
•••
M101
X
View Profile
View Bullboard History
Post by
M101
on Mar 20, 2024 12:33pm
good for recruiting?
https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.13764 https://www.labcorp.com/newsroom
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Significant New Silver Discoveries in the Famous Keno Hill District in the Yukon
This Gambling Tech Stock is Future-Proofing the World’s Casinos and has No Direct Competition
Silvercorp to Acquire Adventus, Creating a Geographically Diversified Mining Company
Revolutionary Tech Company Announces Fourth Quarter and Full Year 2023 Results
Drill Permit Approval Received for New Mexico Lithium Project
This profitable gold stock is on its way up
Mullen Group Ltd. Reports 2024 First Quarter Financial Results